Aliases & Classifications for Mucinoses

MalaCards integrated aliases for Mucinoses:

Name: Mucinoses 12 42 14 69

External Ids:

Disease Ontology 12 DOID:3141
MeSH 42 D017520
SNOMED-CT 64 11528001
UMLS 69 C0162855

Summaries for Mucinoses

MalaCards based summary : Mucinoses is related to herpangina and prostate adenoid cystic carcinoma. An important gene associated with Mucinoses is CHST11 (Carbohydrate Sulfotransferase 11), and among its related pathways/superpathways are Allograft rejection and Interferon gamma signaling. The drugs Polidocanol and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include bone, eye and brain, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Related Diseases for Mucinoses

Graphical network of the top 20 diseases related to Mucinoses:



Diseases related to Mucinoses

Symptoms & Phenotypes for Mucinoses

MGI Mouse Phenotypes related to Mucinoses:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 CD44 FBN1 IFNB1 IFNG INS KRT14
2 endocrine/exocrine gland MP:0005379 9.8 CD44 FBN1 IFNG INS KRT14
3 immune system MP:0005387 9.8 CD44 FBN1 IFNB1 IFNG INS KRT14
4 digestive/alimentary MP:0005381 9.73 KRT14 CD44 IFNG INS
5 muscle MP:0005369 9.56 CD44 FBN1 IFNG INS
6 renal/urinary system MP:0005367 9.46 CD44 FBN1 IFNG INS
7 respiratory system MP:0005388 9.35 CD44 CHST11 FBN1 IFNG KRT14
8 skeleton MP:0005390 9.1 CD44 CHST11 FBN1 IFNB1 IFNG INS

Drugs & Therapeutics for Mucinoses

Drugs for Mucinoses (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Polidocanol Approved Phase 4 9002-92-0
2
Ranibizumab Approved Phase 4 347396-82-1 459903
3
Ropivacaine Approved Phase 4,Phase 3 84057-95-4 71273 175805
4
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
5
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
6
Guaifenesin Approved, Vet_approved Phase 4 93-14-1 3516
7
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569
8
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 2 76-42-6 5284603
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
10
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
11
Nicotinamide Approved, Nutraceutical Phase 4 98-92-0 936
12 Tocopherol Approved, Nutraceutical Phase 4,Phase 2
13
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-02-9 14985
14 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
15 Angiogenesis Inhibitors Phase 4
16 Angiogenesis Modulating Agents Phase 4
17 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
18 Anesthetics, Local Phase 4,Phase 3,Phase 2,Phase 1
19 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Antiemetics Phase 4
22 Antimetabolites Phase 4,Phase 1,Phase 2
23 Antioxidants Phase 4
24 Autonomic Agents Phase 4
25 Gastrointestinal Agents Phase 4
26 Hypolipidemic Agents Phase 4
27 Lipid Regulating Agents Phase 4
28 Micronutrients Phase 4
29 Nicotinic Acids Phase 4
30 Protective Agents Phase 4,Phase 1,Phase 2
31 Tocopherols Phase 4,Phase 2
32 Tocotrienols Phase 4,Phase 2
33 Trace Elements Phase 4
34 Vasodilator Agents Phase 4
35 Vitamin B Complex Phase 4
36 Vitamins Phase 4,Phase 2
37 Antibodies Phase 4,Phase 1,Phase 2
38 Immunoglobulins Phase 4,Phase 1,Phase 2
39 Analgesics Phase 4,Phase 2
40 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
41 Antirheumatic Agents Phase 4,Phase 1,Phase 2
42 Acetaminophen, hydrocodone drug combination Phase 4
43 Analgesics, Non-Narcotic Phase 4,Phase 2
44 Analgesics, Opioid Phase 4,Phase 2
45 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
46 Antipyretics Phase 4,Phase 2
47 Antitussive Agents Phase 4
48 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
49 Cyclooxygenase Inhibitors Phase 4,Phase 2
50 Narcotics Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 178)

id Name Status NCT ID Phase Drugs
1 An Assessment of Intra-lesional 3% Polidocanol Solution in the Treatment of Digital Myxoid Cyst Unknown status NCT02154789 Phase 4 polidocanol
2 Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema Unknown status NCT02055911 Phase 4 Ranibizumab
3 Sleep Quality After Stellate-ganglion Block of Patients Undergoing Breast Cancer Operation Completed NCT02651519 Phase 4 0.25% ropivacaine hydrochloride;saline
4 Effect of Stellate Ganglion Block on Meniere's Disease Completed NCT01574313 Phase 4 0.25mg, fludiazine;25mg cephadol@ (diphenidol);200mg kentons@ (tocopherol nicotinate).
5 Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy Completed NCT00607386 Phase 4
6 A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI Completed NCT00299000 Phase 4 Naglazyme
7 A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease Completed NCT00144781 Phase 4
8 A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients Completed NCT00144768 Phase 4 laronidase
9 Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age Recruiting NCT02455622 Phase 4 Elaprase for intravenous (IV) infusion
10 A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants Recruiting NCT00418821 Phase 4
11 Post-operative Analgesia in Elective, Soft-tissue Hand Surgery Enrolling by invitation NCT02029235 Phase 4 Acetaminophen/Hydrocodone;Acetaminophen/Ibuprofen
12 Morquio's Syndrome: a Case Study Terminated NCT00609440 Phase 4
13 Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Unknown status NCT01238328 Phase 2, Phase 3 Conditioning regimen;Graft-versus-host disease (GVHD) prophylaxis
14 BMN 110 Phase 3B in Australian Patients Unknown status NCT01966029 Phase 3 BMN 110
15 Surgery Versus Manual Rupture for Dorsal Carpal Ganglion Completed NCT01017900 Phase 3
16 A Phase 3 Study of UX003 rhGUS Enzyme Replacement Therapy in Patients With MPS 7 Completed NCT02230566 Phase 3 UX003
17 A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Completed NCT01275066 Phase 3 BMN 110 Weekly;Placebo;BMN 110 Every Other Week
18 Study of rhASB in Patients With Mucopolysaccharidosis VI Completed NCT00104234 Phase 3 N-acetylgalactosamine 4-sulfatase;Placebo/rhASB
19 Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II) Completed NCT00069641 Phase 2, Phase 3
20 Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI Completed NCT00067470 Phase 3 Placebo;N-acetylgalactosamine 4-sulfatase
21 Safety and Efficacy of Hunterase Completed NCT01645189 Phase 3
22 Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Completed NCT01415427 Phase 3 BMN 110 - Weekly;BMN 110 - Every Other Week
23 Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I Completed NCT00912925 Phase 3
24 Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase Completed NCT00630747 Phase 2, Phase 3
25 Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease Completed NCT00258011 Phase 3
26 Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients Completed NCT00146770 Phase 3
27 Infiltration in the Region of the Palatine Ganglion Spheno by Ropivacaine on Postoperative Pain Recruiting NCT02821169 Phase 3 ropivacaine;saline solution 0.9%
28 A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7 Active, not recruiting NCT02432144 Phase 3 UX003
29 Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment Active, not recruiting NCT02055118 Phase 2, Phase 3
30 Long-Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Patients With Hunter Syndrome That Have Completed Study HGT-HIT-094 Enrolling by invitation NCT02412787 Phase 2, Phase 3 Idursulfase-IT
31 ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases Terminated NCT00654433 Phase 3
32 Clinical Trial of Growth Hormone in MPS I, II, and VI Terminated NCT00748969 Phase 2, Phase 3 Somatropin (DNA origin)
33 The Efficacy of Stellate Ganglion Block as Post-traumatic Stress Disorder (PTSD) Therapy: A Pilot Study Unknown status NCT01533610 Phase 2
34 Analgesic Effect of an Injection of Botulinum Toxin Type A in the Ganglion Impar in Patients With Chronic Proctalgia Completed NCT01331356 Phase 2 Botox
35 A Study of JR-141 in Patients With Mucopolysaccharidosis Type II Completed NCT03128593 Phase 1, Phase 2 JR-141
36 Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI Completed NCT02437253 Phase 1, Phase 2 Adalimumab
37 Long-term Follow-up of Sanfilippo Type A Patients Treated by Intracerebral SAF-301 Gene Therapy Completed NCT02053064 Phase 1, Phase 2
38 An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With MPS 7 Completed NCT01856218 Phase 1, Phase 2 UX003
39 Intracerebral Gene Therapy for Sanfilippo Type A Syndrome Completed NCT01474343 Phase 1, Phase 2
40 To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients Completed NCT01301898 Phase 1, Phase 2 GC1111_0.5mg/kg;GC1111_1.0mg/kg;Elaprase_0.5mg/kg
41 A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA Completed NCT00884949 Phase 1, Phase 2 BMN 110
42 Immune Tolerance Study With Aldurazyme® (Laronidase) Completed NCT00741338 Phase 1, Phase 2 Cyclosporine A (CsA);Azathioprine (Aza)
43 Stem Cell Transplantation for Hurler Completed NCT00176917 Phase 2 Busulfan, Cyclophosphamide, ATG
44 Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI Completed NCT00048711 Phase 2 N-acetylgalactosamine 4-sulfatase
45 Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome) Completed NCT00004454 Phase 1, Phase 2
46 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease Completed NCT02060526 Phase 2 Recombinant human heparan N-sulfatase [rhHNS]
47 Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome) Completed NCT01515956 Phase 2 BMN 110
48 Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients Completed NCT01155778 Phase 1, Phase 2
49 A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® Completed NCT00920647 Phase 1, Phase 2 Idursulfase IT (1 mg);Idursulfase IT (10 mg);Idursulfase IT (30 mg)
50 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2

Search NIH Clinical Center for Mucinoses

Cochrane evidence based reviews: mucinoses

Genetic Tests for Mucinoses

Anatomical Context for Mucinoses

MalaCards organs/tissues related to Mucinoses:

39
Bone, Eye, Brain, Bone Marrow, Testes, Dorsal Root Ganglion, Trigeminal Ganglion

Publications for Mucinoses

Articles related to Mucinoses:

(show all 15)
id Title Authors Year
1
Review of Primary Cutaneous Mucinoses in Nonlupus Connective Tissue Diseases. ( 28673091 )
2017
2
Cutaneous mucinoses complicating interferon beta-1b therapy. ( 11844903 )
2002
3
Diffuse cutaneous mucinoses. ( 12170882 )
2002
4
Cutaneous mucinoses: microscopic criteria for diagnosis. ( 11391115 )
2001
5
Cutaneous mucinoses and HIV infection. ( 9990377 )
1998
6
The dermal mucinoses. ( 7694631 )
1993
7
Cutaneous toxic mucinoses. ( 1583189 )
1992
8
The new cutaneous mucinoses: a review with an up-to-date classification of cutaneous mucinoses. ( 2007673 )
1991
9
Focal mucinosis in dogs: seven cases and review of cutaneous mucinoses of man and animals. ( 3962080 )
1986
10
The cutaneous mucinoses. ( 2419372 )
1986
11
The acquired cutaneous mucinoses. ( 6486981 )
1984
12
Multiple cutaneous focal mucinoses with hypothyroidism. ( 7053704 )
1982
13
Reticular erythematous mucinosis (REM syndrome) of Steigleder: its relationship to other mucinoses and to chronic erythemata. ( 747554 )
1978
14
The cutaneous mucinoses. ( 4196237 )
1973
15
Histochemical study of acid mucopolysaccharides in mucinoses. ( 13986611 )
1962

Variations for Mucinoses

Expression for Mucinoses

Search GEO for disease gene expression data for Mucinoses.

Pathways for Mucinoses

GO Terms for Mucinoses

Cellular components related to Mucinoses according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 C4A CXCL9 FBN1 IFNB1 IFNG INS
2 endoplasmic reticulum lumen GO:0005788 9.33 C4A FBN1 INS
3 extracellular space GO:0005615 9.17 C4A CXCL9 FBN1 IFNB1 IFNG INS

Biological processes related to Mucinoses according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.33 C4A FBN1 INS
2 humoral immune response GO:0006959 9.32 IFNB1 IFNG
3 positive regulation of nitric oxide biosynthetic process GO:0045429 9.26 IFNG INS
4 defense response to virus GO:0051607 9.13 CXCL9 IFNB1 IFNG
5 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 8.62 IFNB1 IFNG

Molecular functions related to Mucinoses according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 CXCL9 IFNB1 IFNG

Sources for Mucinoses

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....